Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. VZ
10. SPY

Go back to Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 3c

Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results

July 28, 2021 4:01 PM EDT

WASHINGTON, July 28, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021.

"Vanda had another outstanding quarter of commercial revenue growth as we resumed activity across a number of our clinical programs. Our tradipitant in gastroparesis program is nearing completion, bringing us closer to a much-needed new treatment option for patients with gastroparesis and a potentially transformational commercial opportunity for Vanda," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.

Financial... More